Upstream Processing

Pic:getty/markrubens

BioNTech acquires GMP manufacturing site in Singapore

By Rachel Arthur

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

© GettyImages/Monty Rakusen

Lonza: N-1 perfusion capability enables increased process titers

By Jane Byrne

The biopharma sector has seen recent advancements in process intensification, especially in relation to upstream processing, with the technology employed aimed at increasing drug output. One of the quickest and simplest ways to achieve process intensification...

© GettyImages/Dr_Microbe

Charles River looks to speed up viral vector manufacturing

By Jane Byrne

Charles River Laboratories International has launched a new AAV based platform that it claims has the capability to reduce time from process development to GMP by 55% and deliver a drug product in fewer than eight months.

Pic:getty/igorvershinsky

Building up Australia’s vaccine manufacturing capacity

By Rachel Arthur

Almost all of Australia’s vaccines are imported: creating a potential crisis in a pandemic. As a result, the country is setting out its strategy for developing vaccine manufacturing capabilities.

Pic:getty/alengo

US government provides funds to boost continuous bioprocessing

By Ben Hargreaves

Despite continuous bioprocessing being talked about as the future of manufacturing in biologics for years, this has not become reality. However, in recent years, the US government has begun to dedicate funds to intensify the production of biologics.

Pic:getty/markrubens

WuXi Biologics to build CRDMO center in Singapore

By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

Follow us

Products

View more

Webinars